Showing 20 of 62 recruiting trials for “marginal-zone-lymphoma”
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
👨⚕️ Gottfried von Keudell, MD, PhD, Beth Israel Deaconess Medical Center📍 1 site📅 Started Feb 2026View details ↗
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
👨⚕️ Shuhua yi, Hematology Hospital, Chinese Academy of Medical Sciences📍 14 sites📅 Started Jan 2026View details ↗
Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.
RecruitingNCT06712459 ↗
Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma
👨⚕️ Luca Arcaini, MD, Fondazione IRCCS Policlinico San Matteo📍 7 sites📅 Started Oct 2025View details ↗
Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants
A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA）
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain
A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas
👨⚕️ François LEMONNIER, Pr, Hôpital Henri Mondor - Lymphoid Malignancies Unit📍 20 sites📅 Started Aug 2025View details ↗
Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
🏥 The First Affiliated Hospital with Nanjing Medical University📍 1 site📅 Started Aug 2025View details ↗
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma
Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
🏥 The First Affiliated Hospital with Nanjing Medical University📍 1 site📅 Started Apr 2025View details ↗
Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Page 1 of 4Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →